object
mani
adult
patient
hospitalis
acut
respiratori
ill
virus
detect
overal
import
viral
infect
compar
bacteri
infect
unclear
method
patient
recruit
two
acut
hospit
site
leicest
uk
success
winter
sampl
taken
viral
bacteri
test
result
patient
hospitalis
acut
respiratori
ill
respiratori
viru
detect
picornavirus
commonli
isol
virus
detect
patient
viru
detect
rate
exceed
patient
exacerb
asthma
acut
bronchiti
influenzalikeil
rang
patient
exacerb
copd
commun
acquir
pneumonia
congest
cardiac
failur
bacteri
detect
rel
frequent
patient
exacerb
copd
pneumonia
respect
uncommon
group
antibiot
use
high
across
clinic
group
overal
antibiot
use
occur
patient
detect
bacteria
adult
hospitalis
acut
respiratori
ill
rare
detect
bacteria
absenc
copd
pneumonia
viral
infect
predomin
larg
prospect
uk
sampl
introduct
acut
respiratori
ill
respons
larg
proport
acut
hospit
admiss
adult
accept
respiratori
virus
respons
major
acut
respiratori
ill
infant
children
includ
admit
secondari
care
whilst
respiratori
viral
infect
increasingli
recognis
aetiolog
acut
respiratori
ill
adult
overal
import
compar
bacteria
unclear
respiratori
virus
detect
major
exacerb
asthma
adult
smaller
proport
patient
exacerb
copd
commun
acquir
pneumonia
picornavirus
rhinovirus
enterovirus
frequent
caus
common
cold
also
consist
commonli
detect
virus
adult
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
studi
aetiolog
commun
acquir
pneumonia
addit
recent
evid
suggest
respiratori
virus
associ
signific
proport
acut
respiratori
diseas
amongst
hospitalis
adult
elderli
antibiot
use
common
hospit
recent
us
studi
demonstr
hospit
inpati
receiv
antibiot
stage
stay
acut
respiratori
ill
commonest
reason
antibiot
use
addit
frequent
isol
virus
also
lack
evid
clinic
benefit
antibiot
use
mani
acut
respiratori
condit
present
secondari
care
includ
acut
bronchiti
exacerb
asthma
mildmoder
case
exacerb
chronic
obstruct
airway
diseas
widespread
use
antibiot
hospit
commun
led
emerg
prolifer
antibiot
resist
bacteria
increas
rate
health
care
associ
infect
hcai
clostridium
difficil
effect
antibiot
stewardship
reduct
excess
antibiot
use
hospit
shown
effect
reduc
antimicrobi
resist
hcai
therefor
becom
global
prioriti
studi
sought
defin
microbi
aetiolog
hospitalis
adult
varieti
common
acut
respiratori
syndrom
describ
clinic
characterist
antimicrobi
use
subject
particip
prospect
recruit
trial
rapid
diagnost
test
streptococcu
pneumonia
influenza
met
follow
inclus
criteria
age
year
abl
will
give
written
inform
consent
rel
carer
abl
will
give
inform
assent
acut
exacerb
chronic
cardiopulmonari
ill
h
day
durat
includ
exacerb
copd
asthma
congest
cardiac
failur
acut
pulmonari
ill
day
durat
includ
pneumonia
bronchiti
influenzalik
ill
recruit
studi
within
period
initi
assess
medic
admiss
unit
abl
will
adher
procedur
state
protocol
demograph
clinic
data
present
symptom
sign
comorbid
medic
use
prior
antibiot
use
smoke
histori
vaccin
statu
collect
enrol
record
standardis
case
report
form
radiolog
laboratori
data
collat
retrospect
use
computeris
imag
laboratori
system
patient
chest
radiograph
perform
within
h
admiss
individu
clinic
group
identifi
discharg
intern
classif
diseas
tenth
edit
code
classif
confirm
case
note
review
full
detail
clinic
group
definit
given
appendix
b
standard
microbiolog
test
blood
urin
sputum
nasopharyng
swab
sampl
collect
enrol
blood
cultur
incub
aerob
anaerob
use
bactalert
blood
cultur
system
biomerieux
durham
north
carolina
usa
sputum
examin
gram
stain
microscopi
cultur
sheep
blood
agar
chocol
agar
plate
incub
aerob
co
c
read
h
h
urin
test
pneumonia
antigen
use
pneumonia
urinari
antigen
test
binax
portland
main
usa
nasopharyng
swab
store
viral
transport
medium
frozen
c
prior
test
urin
test
legionella
pneumophilia
binax
portland
main
usa
antigen
physician
discret
patient
pneumonia
quadriplex
influenza
realtim
assay
includ
intern
control
bacteriophag
detail
elsewher
three
addit
multiplex
realtim
taqman
pcr
assay
employ
detect
remain
respiratori
virus
includ
respiratori
syncyti
viru
rsv
b
parainfluenza
piv
type
adenoviru
enteroviru
rhinoviru
human
metapneumoviru
hmpv
group
coronavirus
group
coronavirus
sar
associ
coronaviru
full
detail
pcr
method
includ
primer
probe
sequenc
given
appendix
c
statist
analysi
perform
use
prism
version
graphpad
softwar
la
jolla
ca
spss
version
spss
inc
chicago
il
nonparametr
data
describ
median
interquartil
rang
mannewhitney
u
test
use
compar
group
proport
compar
use
c
fisher
exact
test
clopperpearson
method
use
calcul
confid
interv
ci
proport
p
valu
taken
threshold
statist
signific
crp
mgl
consid
equal
mgl
statist
purpos
total
patient
studi
trial
profil
shown
fig
demograph
clinic
laboratori
outcom
data
clinic
group
shown
tabl
overal
patient
hospitalis
acut
respiratori
ill
respiratori
virus
detect
picrornavirus
rhinoviru
enteroviru
frequent
identifi
viru
detect
patient
either
alon
anoth
respiratori
viru
influenza
b
virus
detect
patient
altogeth
human
metapneumoviru
coronavirus
group
parainfluenza
viru
type
detect
patient
admiss
associ
rsv
adenoviru
detect
patient
combin
codetect
two
differ
respiratori
virus
occur
patient
tabl
show
rate
respiratori
viru
detect
patient
clinic
group
fig
picornavirus
commonli
detect
patient
asthma
compar
clinic
group
p
wherea
influenza
viru
detect
commonli
associ
acut
bronchitisili
p
fig
show
respiratori
viru
detect
rate
clinic
condit
bacteria
detect
patient
acut
respiratori
ill
overal
tabl
show
bacteri
detect
clinic
group
bacteri
detect
common
patient
pneumonia
patient
exacerb
copd
patient
compar
clinic
group
p
pneumonia
commonli
identifi
bacteri
pathogen
detect
patient
posit
test
bacteria
mix
viral
bacteri
detect
also
common
patient
pneumonia
patient
exacerb
copd
patient
compar
clinic
group
p
detect
bacteria
uncommon
patient
hospitalis
exacerb
asthma
patient
heart
failur
patient
acut
bronchiti
ili
patient
fig
show
proport
patient
virus
detect
alon
bacteria
detect
alon
bacteria
virus
detect
togeth
case
pathogen
isol
although
patient
nasopharyng
swab
test
virus
vast
major
patient
blood
cultur
pneumococc
antigen
test
perform
abl
produc
sputum
sampl
cultur
therefor
perform
separ
analysi
patient
complet
sampl
bacteria
sputum
cultur
blood
cultur
pneumococc
antigen
test
among
subgroup
overal
rate
bacteri
detect
higher
main
cohort
patient
pneumonia
versu
exacerb
copd
versu
remain
low
asthma
heart
failur
acut
bronchitisili
shown
tabl
overal
antibiot
given
patient
hospitalis
acut
respiratori
ill
least
one
dose
intraven
iv
antibiot
administ
antibiot
use
high
across
clinic
group
antibiot
given
patient
pneumonia
receiv
least
dose
iv
antibiot
patient
exacerb
copd
receiv
antibiot
receiv
iv
antibiot
antibiot
given
patient
exacerb
asthma
receiv
iv
antibiot
patient
heart
failur
patient
acut
bronchitisili
receiv
antibiot
patient
treat
neuraminidas
inhibitor
antivir
agent
whilst
hospitalis
antimicrobi
treatment
clinic
group
shown
tabl
examin
antibiot
use
aetiolog
show
overal
patient
virus
detect
alon
given
antibiot
repres
antibiot
use
acut
respiratori
ill
antibiot
use
occur
patient
bacteria
detect
e
either
alon
concurr
viru
patient
pathogen
detect
receiv
antibiot
repres
antibiot
use
antibiot
use
aetiolog
shown
fig
one
largest
studi
examin
microbi
aetiolog
hospitalis
adult
acut
respiratori
virus
adult
acut
respiratori
ill
ill
contain
within
largest
cohort
hospitalis
patient
copd
systemat
test
respiratori
virus
agreement
recent
studi
demonstr
import
respiratori
virus
larg
burden
picornaviru
infect
addit
trigger
exacerb
asthma
copd
caus
lower
respiratori
tract
ill
communitydwel
elderli
work
suggest
picornavirus
import
larg
proport
adult
hospitalis
acut
respiratori
ill
studi
show
bacteri
detect
rel
frequent
patient
exacerb
copd
pneumonia
mix
detect
bacteria
virus
also
common
compar
clinic
group
detect
bacteria
rare
agreement
similar
studi
antibiot
use
high
across
clinic
group
relat
aetiolog
vast
major
antibiot
use
took
place
patient
without
detect
bacteri
infect
includ
signific
amount
intraven
antibiot
use
compar
recent
similar
studi
hospitalis
adult
acut
respiratori
ill
found
lower
rate
bacteri
codetect
among
patient
virus
detect
like
explain
author
use
procalcitonin
pct
level
ngml
defin
bacteri
infect
addit
actual
detect
bacteria
whilst
pct
level
patient
acut
respiratori
ill
tend
higher
patient
bacteria
detect
compar
virus
detect
viral
infect
frequent
associ
pct
level
ngml
independ
bacteria
strategi
reduc
excess
antibiot
use
urgent
need
must
balanc
risk
undertr
genuin
sever
bacteri
infect
patient
pneumonia
complic
mortal
rate
high
evid
exist
benefit
time
antibiot
treatment
high
rate
antibiot
use
seem
justifi
appropri
although
virus
frequent
detect
patient
pneumonia
codetect
bacteria
also
common
secondari
bacteri
pneumonia
follow
respiratori
viral
infect
known
occur
primari
viral
pneumonia
occur
nonimmunocompromis
adult
influenza
viru
infect
may
also
occur
respiratori
virus
howev
definit
exclud
concurr
bacteri
infect
patient
often
sever
unwel
difficult
achiev
practic
strategi
reduc
antibiot
use
hospitalis
patient
pneumonia
unlik
appropri
success
detect
rate
respiratori
virus
patient
exacerb
copd
around
consist
find
recent
systemat
review
although
antibiot
use
common
occur
around
patient
bacteri
detect
codetect
virus
bacteria
togeth
also
rel
common
suggest
viral
identif
patient
exacerb
copd
use
isol
withhold
antibiot
therapi
although
bacteria
frequent
detect
patient
exacerb
copd
exact
role
import
compar
virus
subject
ongo
debat
antibiot
current
recommend
copd
exacerb
accord
clinic
criteria
howev
evid
clinic
benefit
mild
moder
exacerb
limit
must
balanc
risk
advers
event
studi
use
serum
biomark
procalcitonin
pct
demonstr
antibiot
safe
withheld
patient
exacerb
copd
low
level
pct
biomark
direct
antibiot
use
probabl
repres
promis
strategi
current
avail
reduc
excess
antibiot
use
group
studi
evalu
ongo
keep
previou
studi
identifi
respiratori
viru
around
patient
hospitalis
exacerb
asthma
major
picornavirus
influenza
viru
detect
asthma
exacerb
studi
notabl
asthma
risk
factor
hospit
admiss
laboratori
confirm
influenza
recent
pandem
cohort
bacteri
detect
patient
exacerb
asthma
unusu
although
test
atyp
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
role
trigger
exacerb
asthma
establish
trial
antibiot
activ
organ
shown
benefit
asthmat
subject
despit
high
preval
viral
infect
lack
evid
clinic
benefit
antibiot
nation
guidelin
discourag
use
antibiot
still
use
major
hospitalis
asthmat
patent
whilst
often
cite
reason
cardiac
decompens
causal
relationship
acut
decompens
congest
cardiac
failur
respiratori
viru
infect
well
establish
larg
studi
us
demonstr
rsv
influenza
virus
associ
signific
proport
hospitalis
congest
heart
failur
studi
around
one
third
patient
admit
decompens
heart
failur
respiratori
viru
detect
bacteria
detect
infrequ
antibiot
use
major
detect
respiratori
virus
around
two
third
patient
acut
bronchiti
ili
combin
compar
find
previou
studi
contrast
bacteria
rare
detect
although
antibiot
use
common
recent
randomis
placebo
control
trial
antibiot
acut
bronchiti
patient
without
chronic
lung
diseas
demonstr
benefit
antibiot
trend
toward
harm
age
year
cochran
review
conclud
limit
evid
use
antibiot
acut
bronchiti
discourag
use
group
studi
greater
proport
patient
acut
bronchitisili
influenza
viru
detect
compar
clinic
group
although
viru
type
also
frequent
detect
total
influenza
viru
detect
patient
acut
respiratori
ill
influenza
respiratori
viru
specif
antivir
agent
exist
howev
patient
studi
prescrib
neuraminidas
inhibitor
ni
either
hospit
admiss
contrast
us
cdc
guidelin
uk
nice
guidanc
advoc
use
ni
start
within
h
symptom
onset
irrespect
hospitalis
statu
sever
use
even
restrict
criteria
nineteen
patient
laboratori
confirm
influenza
studi
present
within
h
onset
symptom
therefor
consid
treatment
addit
evid
recent
larg
observ
studi
suggest
ni
may
reduc
mortal
pandem
influenza
among
hospitalis
adult
even
start
h
symptom
durat
sever
limit
studi
result
applic
hospitalis
adult
extrapol
children
patient
present
primari
care
season
natur
recruit
mean
result
applic
patient
admit
outsid
summer
month
may
overestim
overal
annual
incid
respiratori
viral
detect
patient
group
addit
exact
date
patient
recruit
differ
year
year
potenti
underestim
preval
respiratori
virus
season
period
rsv
influenza
may
explain
rel
low
rate
rsv
detect
compar
studi
definit
bacteri
detect
includ
isol
potenti
pathogen
bacteria
sputum
may
overestim
true
number
bacteri
infect
presenc
bacteria
sputum
may
repres
colonis
rather
infect
test
pneumonia
c
pneumonia
studi
may
underestim
overal
proport
bacteri
detect
howev
role
organ
clinic
group
pneumonia
bronchiti
establish
similar
studi
hospitalis
adult
shown
low
rate
detect
even
use
molecular
method
cohort
larg
number
patient
unabl
provid
adequ
sputum
sampl
analysi
cultur
could
underestim
overal
rate
bacteri
detect
howev
subgroup
analysi
patient
complet
sampl
overal
rate
bacteri
detect
higher
patient
copd
pneumonia
group
significantli
differ
final
around
quarter
patient
alreadi
take
antibiot
time
hospitalis
could
led
reduct
detect
bacteria
underestim
bacteri
detect
rate
howev
notabl
detect
rate
bacteria
studi
consist
similar
studi
includ
patient
alreadi
antibiot
exclud
summari
studi
demonstr
predomin
respiratori
virus
adult
hospitalis
acut
respiratori
ill
show
excess
antibiot
use
occur
clinic
group
viral
detect
common
bacteri
detect
rare
lack
evid
clinic
benefit
antibiot
effort
reduc
excess
antibiot
use
hospit
focu
group
prioriti
view
opinion
express
manuscript
author
necessarili
reflect
hta
programm
nihr
nh
depart
health
twc
involv
design
studi
perform
molecular
laboratori
work
data
collect
statist
analysi
wrote
manuscript
mm
involv
design
studi
perform
molecular
laboratori
work
involv
write
manuscript
sb
involv
design
studi
write
manuscript
mc
involv
design
studi
molecular
method
write
manuscript
sp
involv
design
studi
molecular
method
write
manuscript
kgn
involv
design
studi
data
analysi
write
manuscript
twc
act
guarantor
paper
take
respons
integr
work
whole
incept
publish
articl
